THE SUBSTRATE-BINDING SITE OF HUMAN LIVER CYTOCHROME-P450 2C9 - AN APPROACH USING DESIGNED TIENILIC ACID-DERIVATIVES AND MOLECULAR MODELING

被引:116
作者
MANCY, A
BROTO, P
DIJOLS, S
DANSETTE, PM
MANSUY, D
机构
[1] UNIV PARIS 05, CHIM & BIOCHIM PHARMACOL & TOXICOL LAB, CNRS, URA 400, F-75270 PARIS 06, FRANCE
[2] ROUSSEL UCLAF, DIRECT RECH, F-93230 ROMAINVILLE, FRANCE
关键词
D O I
10.1021/bi00033a007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biochemical experiments, using the well-defined human liver CYP2C9 expressed in yeast, and molecular modeling techniques were used to derive a predictive model for substrates of CYP2C9. The ability of 10 2-aroylthiophenes related to tienilic acid to act as substrates for CYP2C9 was studied. Four of them were original compounds that were synthesized and completely characterized by several spectroscopic techniques. In these 10 compounds various chemical functions, such as ester, amide, alcohol, phenol, ether or tetrazole functions, replaced the OCH2COOH function of tienilic acid. Among them, only the derivatives containing an acidic function (carboxylic acids, phenol, and tetrazole whose pK(a)s are 4.8, 6.3, and 3.8, respectively) underwent a 5-hydroxylation of their thiophene ring like tienilic acid. Despite their close structural analogy with tienilic acid, all of the other compounds not only did not undergo any 5-hydroxylation of their thiophene ring but also failed to act as inhibitors of CYP2C9. These results strongly suggested that the presence, at pH 7.4, of a negative charge on the substrate is a very important feature in its recognition by CYP2C9. In fact, the four new substrates of CYP2C9 described in this study, a carboxylic acid, phenol, and tetrazole derivative, each of which is related to tienilic acid, and the antiinflammatory drug, suprofen (with K-m between 12 and 130 mu M and k(cat) between 0.2 and 1.3 min(-1)), as well as almost all CYP2C9 substrates reported in the literature, exhibit a pK(a) below 7 (except phenytoin whose pK(a) is 8.1). They mainly exist as anions at physiological pH. By using molecular modeling techniques, 12 CYP2C9 substrates were superimposed with respect to their hydroxylation site and fitted onto templates, which were rigid molecules such as (S)-warfarin and phenyboin. It was thus possible to arrange them in order that all their anionic sites were at a distance around 4 Angstrom from a common point (a putative cationic site of the protein) in space. These results provide a model of the substrate binding site of CYP2C9, in which substrates interact through their anionic site A(-) with a cationic residue. In that model, the distance between the hydroxylation site (Hy) and the anionic site (A(-)) is 7.8 +/- 1.6 Angstrom, and the angle HyA(-)C(+) angle is 82 +/- 15 degrees.
引用
收藏
页码:10365 / 10375
页数:11
相关论文
共 62 条
  • [1] ALEXANDER RR, 1993, BASIC BIOCH METHODS, P7
  • [2] 5 OF 12 FORMS OF VACCINIA VIRUS-EXPRESSED HUMAN HEPATIC CYTOCHROME-P450 METABOLICALLY ACTIVATE AFLATOXIN-B1
    AOYAMA, T
    YAMANO, S
    GUZELIAN, PS
    GELBOIN, HV
    GONZALEZ, FJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) : 4790 - 4793
  • [3] THE COMPUTER-PROGRAM LUDI - A NEW METHOD FOR THE DENOVO DESIGN OF ENZYME-INHIBITORS
    BOHM, HJ
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1992, 6 (01) : 61 - 78
  • [4] BONNABRY P, 1994, CLIN PHARMACOL THER, V55, P139
  • [5] BORHEIM LM, 1992, DRUG METAB DISPOS, V20, P241
  • [6] EXPRESSION OF A HUMAN-LIVER CYTOCHROME-P-450 PROTEIN WITH TOLBUTAMIDE HYDROXYLASE-ACTIVITY IN SACCHAROMYCES-CEREVISIAE
    BRIAN, WR
    SRIVASTAVA, PK
    UMBENHAUER, DR
    LLOYD, RS
    GUENGERICH, FP
    [J]. BIOCHEMISTRY, 1989, 28 (12) : 4993 - 4999
  • [7] HUMAN-LIVER MEPHENYTOIN 4'-HYDROXYLASE CYTOCHROME-P-450 PROTEINS AND GENES
    BRIAN, WR
    GED, C
    BELLEW, TM
    SRIVASTAVA, PK
    BORK, RW
    UMBENHAUER, DR
    LLOYD, RS
    GUENGERICH, FP
    [J]. DRUG METABOLISM REVIEWS, 1989, 20 (2-4) : 449 - 465
  • [8] STEREOCHEMICAL BASIS OF ANTICONVULSANT DRUG ACTION .1. CRYSTAL AND MOLECULAR STRUCTURE OF DIPHENYLHYDANTOIN, A NONCENTROSYMMETRIC STRUCTURE SOLVED BY CENTRIC SYMBOLIC ADDITION
    CAMERMAN, A
    CAMERMAN, N
    [J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, 1971, B 27 (NOV15): : 2205 - &
  • [9] [2,3-DICHLORO-4-(2-THENOYL) PHENOXY] ACETIC-ACID (TIENILIC ACID)
    CARPY, A
    GOURSOLLE, M
    LEGER, JM
    [J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1980, 36 (JUL): : 1706 - 1708
  • [10] CASTLE MC, 1988, ARCH INT PHARMACOD T, V295, P7